莱茵生物(002166) - 2021 Q3 - 季度财报

Financial Performance - Revenue for Q3 2021 reached ¥259,391,381.67, an increase of 59.19% compared to the same period last year[3] - Net profit attributable to shareholders was ¥27,972,041.45, representing a 128.97% increase year-on-year[3] - Year-to-date revenue totaled ¥712,251,076.35, up 60.56% from the previous year[3] - Basic earnings per share for Q3 2021 was ¥0.05, a 150.00% increase compared to the same period last year[3] - The company achieved a total operating revenue of CNY 712.25 million in the third quarter of 2021, representing a year-on-year growth of 60.56%[16] - The net profit attributable to shareholders of the listed company was CNY 87.60 million, an increase of 32.61% compared to the same period last year[16] - Operating profit rose to CNY 344.83 million, a 137.63% increase, attributed to higher sales and effective cost control[11] - Net profit for the current period was ¥95,049,013.36, representing a 43.9% increase from ¥66,056,817.03 in the previous period[31] - The company reported a comprehensive income total of ¥91,668,573.14, compared to ¥56,840,848.10 in the prior period, indicating a growth of 61.4%[32] - Basic and diluted earnings per share increased to ¥0.15 from ¥0.12, reflecting a growth of 25%[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,006,545,738.98, a decrease of 4.93% from the end of the previous year[4] - The company's total assets decreased to approximately 3.01 billion RMB as of September 30, 2021, down from 3.16 billion RMB at the end of 2020[29] - The company's total liabilities decreased to approximately 1.13 billion RMB as of September 30, 2021, compared to 1.35 billion RMB at the end of 2020[28] - The total liabilities and equity combined amounted to CNY 3,162,557,184.02, ensuring a balanced financial structure[40] - Total liabilities amounted to CNY 793,348,737.63, with current liabilities at CNY 640,019,844.31[43] - Non-current liabilities totaled CNY 153,328,893.32, including deferred income of CNY 126,511,306.31 and deferred tax liabilities of CNY 26,817,587.01[43] Cash Flow - Cash flow from operating activities for the year-to-date was ¥178,920,160.92, down 25.13% compared to the previous year[3] - The net cash flow from operating activities was CNY 76.51 million, a decrease of 32.05% due to increased payments for raw materials[12] - The company reported a total net cash flow from financing activities of CNY -132.60 million, a decline of 234.90% due to reduced new bank loans[12] - Cash flow from operating activities generated a net cash inflow of ¥178,920,160.92, down from ¥238,987,217.42 in the previous period[34] - Cash and cash equivalents at the end of the period decreased to ¥119,043,168.43 from ¥250,440,957.13, a decline of 52.4%[35] - Investment activities resulted in a net cash outflow of ¥68,835,831.99, compared to a larger outflow of ¥257,181,034.45 in the previous period[34] - Financing activities led to a net cash outflow of ¥132,599,755.34, contrasting with a net inflow of ¥98,296,408.34 in the prior period[35] Research and Development - Research and development expenses increased by 175.61% year-on-year, amounting to ¥25,206,415.86[10] - Research and development expenses increased by 152.20% to CNY 10.09 million, indicating a significant investment in innovation[11] - The company has increased its R&D expenses to ¥25,206,415.86, up from ¥9,145,527.03, marking a rise of 175.5%[30] Market and Business Strategy - The company reported a significant increase in plant extraction revenue, contributing to the overall revenue growth[10] - Revenue from the plant extraction business reached CNY 691.12 million, up 76.70% year-on-year, driven by the rising demand for natural sweeteners[16] - The natural sweetener segment generated CNY 417.97 million in revenue, reflecting a 55.08% increase year-on-year, benefiting from the "sugar-free" trend[16] - The company plans to continue expanding its market presence and investing in new product development[10] - The company plans to enhance its natural sweetener business through a non-public offering to solidify its position as a leading global producer[16] - The company is actively expanding its natural sweetener business through collaboration with Firmenich, focusing on product sales, technical exchanges, and customer development[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 48,308[14] - The company received approval from the China Securities Regulatory Commission for a non-public offering of up to 165,470,085 shares, valid for 12 months from the approval date[18] Inventory and Other Assets - The company’s inventory decreased to approximately 507.40 million RMB as of September 30, 2021, from 691.31 million RMB at the end of 2020[25] - The company holds inventory valued at CNY 691,314,076.95, indicating a significant asset base[38] - The company has a long-term investment of CNY 423,634,326.45, indicating strategic growth initiatives[42] Audit Status - The third quarter report for 2021 was not audited, indicating a lack of external verification for the financial data presented[44]